Enzymatica
2.04 SEK
+4.08 %
Less than 1K followers
ENZY
First North Stockholm
Biotechnology & Pharmaceuticals
Health Care
Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Valuation
Income statement
Quarter data
Quarter data
Financial statements, revenue, EBIT, valuation metrics, and quarterly estimates for Enzymatica
| Q3/24 | Q4/24 | 2024 | Q1/25 | Q2/25 | Q3/25 | Q4/25 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | 12.6 | 17.2 | 45.6 | 12.3 | 8.3 | 15.0 | 18.3 | 53.9 |
| EBITDA | -6.4 | -13.7 | -52.1 | -18.0 | -14.9 | -6.8 | ||
| EBIT | -6.4 | -13.7 | -52.1 | -18.0 | -14.9 | -8.2 | -10.2 | -51.4 |
| EBIT-% | -51.1 % | -79.9 % | -114.2 % | -146.5 % | -180.2 % | -54.8 % | -55.8 % | -95.3 % |
| Profit before taxes | -6.9 | -13.3 | -53.3 | -18.2 | -14.5 | -8.2 | -10.9 | -51.8 |
| Net income | -7.3 | -13.3 | -53.2 | -18.0 | -14.5 | -8.4 | -11.0 | -51.9 |